Global Plasma-derived Therapies Supply, Demand and Key Producers, 2024-2030

Description

Plasma-derived Therapies: These are medicinal products that are manufactured from human plasma, the liquid component of blood. Plasma contains important proteins, clotting factors, and antibodies that can be processed and concentrated to create products used in various medical treatments. PDPs are essential for treating conditions such as hemophilia, immune deficiencies, and certain autoimmune diseases.

The global Plasma-derived Therapies market size is expected to reach $ 55550 million by 2030, rising at a market growth of 7.3% CAGR during the forecast period (2024-2030).

Driver of the Plasma-derived Therapies Market:
One of the main drivers of the plasma-derived therapies market is the increasing prevalence of rare and chronic diseases, such as hemophilia, primary immunodeficiency disorders, and autoimmune diseases. These conditions require ongoing treatment with plasma-derived products like clotting factors, immunoglobulins, and albumin. The growing awareness and diagnosis rates of such diseases, along with advancements in plasma collection and fractionation technologies, have contributed to a higher demand for these therapies. Additionally, increasing investments in healthcare infrastructure and government support in emerging markets are fueling market growth.

Challenge of the Plasma-derived Therapies Market:
A key challenge in this market is the complex and costly process of plasma collection and product manufacturing. Plasma-derived therapies require large volumes of plasma, which can only be obtained through human donors. The stringent regulations surrounding plasma collection, donor screening, and testing to ensure safety make the process time-consuming and expensive. Furthermore, any disruption in plasma supply chains, such as those caused by geopolitical issues or pandemics, can lead to shortages and impact treatment availability.

The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.

The classification of Plasma-derived Therapies includes Immune Globulin, Coagulation Factor, Albumin and Other. In 2023, Immune Globulin accounted for a share of 51% in the global Plasma-derived Therapies market.

North America is the largest consumption place, with a revenue market share nearly 40% in 2023. Following North America, Europe is the second largest consumption place with the revenue market share of 24 %; China is also an important sales region for the Plasma-derived Therapies.

This report studies the global Plasma-derived Therapies demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Plasma-derived Therapies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Plasma-derived Therapies that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Plasma-derived Therapies total market, 2019-2030, (USD Million)
Global Plasma-derived Therapies total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Plasma-derived Therapies total market, key domestic companies, and share, (USD Million)
Global Plasma-derived Therapies revenue by player, revenue and market share 2019-2024, (USD Million)
Global Plasma-derived Therapies total market by Type, CAGR, 2019-2030, (USD Million)
Global Plasma-derived Therapies total market by Application, CAGR, 2019-2030, (USD Million)
This report profiles major players in the global Plasma-derived Therapies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Plasma-derived Therapies market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Plasma-derived Therapies Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Plasma-derived Therapies Market, Segmentation by Type
    Immune Globulin
    Coagulation Factor
    Albumin
    Other

Global Plasma-derived Therapies Market, Segmentation by Application:
    Hospital
    Retail Pharmacy
    Other

Companies Profiled:
    Takeda
    CSL
    Grifols
    Octapharma
    Kedrion
    LFB Group
    Biotest
    BPL
    RAAS
    CBPO
    Hualan Bio
    Tiantan Bio
    Shuanglin Bio
    Boya Bio
    Yuanda Shuyang
    Weiguang Bio
    Nanyue Bio
    KM Biologics

Key Questions Answered
1. How big is the global Plasma-derived Therapies market?
2. What is the demand of the global Plasma-derived Therapies market?
3. What is the year over year growth of the global Plasma-derived Therapies market?
4. What is the total value of the global Plasma-derived Therapies market?
5. Who are the Major Players in the global Plasma-derived Therapies market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Plasma-derived Therapies Introduction
    1.2 World Plasma-derived Therapies Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Plasma-derived Therapies Total Market by Region (by Headquarter Location)
        1.3.1 World Plasma-derived Therapies Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.3 China Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.4 Europe Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.5 Japan Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.6 South Korea Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.7 ASEAN Based Company Plasma-derived Therapies Revenue (2019-2030)
        1.3.8 India Based Company Plasma-derived Therapies Revenue (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Plasma-derived Therapies Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Major Market Trends

2 Demand Summary
    2.1 World Plasma-derived Therapies Consumption Value (2019-2030)
    2.2 World Plasma-derived Therapies Consumption Value by Region
        2.2.1 World Plasma-derived Therapies Consumption Value by Region (2019-2024)
        2.2.2 World Plasma-derived Therapies Consumption Value Forecast by Region (2025-2030)
    2.3 United States Plasma-derived Therapies Consumption Value (2019-2030)
    2.4 China Plasma-derived Therapies Consumption Value (2019-2030)
    2.5 Europe Plasma-derived Therapies Consumption Value (2019-2030)
    2.6 Japan Plasma-derived Therapies Consumption Value (2019-2030)
    2.7 South Korea Plasma-derived Therapies Consumption Value (2019-2030)
    2.8 ASEAN Plasma-derived Therapies Consumption Value (2019-2030)
    2.9 India Plasma-derived Therapies Consumption Value (2019-2030)

3 World Plasma-derived Therapies Companies Competitive Analysis
    3.1 World Plasma-derived Therapies Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Plasma-derived Therapies Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Plasma-derived Therapies in 2023
        3.2.3 Global Concentration Ratios (CR8) for Plasma-derived Therapies in 2023
    3.3 Plasma-derived Therapies Company Evaluation Quadrant
    3.4 Plasma-derived Therapies Market: Overall Company Footprint Analysis
        3.4.1 Plasma-derived Therapies Market: Region Footprint
        3.4.2 Plasma-derived Therapies Market: Company Product Type Footprint
        3.4.3 Plasma-derived Therapies Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers & Acquisitions Activity

4 United States VS China VS Rest of World (by Headquarter Location)
    4.1 United States VS China: Plasma-derived Therapies Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Plasma-derived Therapies Revenue Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Plasma-derived Therapies Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Plasma-derived Therapies Consumption Value Comparison
        4.2.1 United States VS China: Plasma-derived Therapies Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Plasma-derived Therapies Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Plasma-derived Therapies Companies and Market Share, 2019-2024
        4.3.1 United States Based Plasma-derived Therapies Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Plasma-derived Therapies Revenue, (2019-2024)
    4.4 China Based Companies Plasma-derived Therapies Revenue and Market Share, 2019-2024
        4.4.1 China Based Plasma-derived Therapies Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Plasma-derived Therapies Revenue, (2019-2024)
    4.5 Rest of World Based Plasma-derived Therapies Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Plasma-derived Therapies Companies, Headquarters (Province, Country)
        4.5.2 Rest of World Based Companies Plasma-derived Therapies Revenue (2019-2024)

5 Market Analysis by Type
    5.1 World Plasma-derived Therapies Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Immune Globulin
        5.2.2 Coagulation Factor
        5.2.3 Albumin
        5.2.4 Other
    5.3 Market Segment by Type
        5.3.1 World Plasma-derived Therapies Market Size by Type (2019-2024)
        5.3.2 World Plasma-derived Therapies Market Size by Type (2025-2030)
        5.3.3 World Plasma-derived Therapies Market Size Market Share by Type (2025-2030)

6 Market Analysis by Application
    6.1 World Plasma-derived Therapies Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Retail Pharmacy
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Plasma-derived Therapies Market Size by Application (2019-2024)
        6.3.2 World Plasma-derived Therapies Market Size by Application (2025-2030)
        6.3.3 World Plasma-derived Therapies Market Size Market Share by Application (2019-2030)

7 Company Profiles
    7.1 Takeda
        7.1.1 Takeda Details
        7.1.2 Takeda Major Business
        7.1.3 Takeda Plasma-derived Therapies Product and Services
        7.1.4 Takeda Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Takeda Recent Developments/Updates
        7.1.6 Takeda Competitive Strengths & Weaknesses
    7.2 CSL
        7.2.1 CSL Details
        7.2.2 CSL Major Business
        7.2.3 CSL Plasma-derived Therapies Product and Services
        7.2.4 CSL Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 CSL Recent Developments/Updates
        7.2.6 CSL Competitive Strengths & Weaknesses
    7.3 Grifols
        7.3.1 Grifols Details
        7.3.2 Grifols Major Business
        7.3.3 Grifols Plasma-derived Therapies Product and Services
        7.3.4 Grifols Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Grifols Recent Developments/Updates
        7.3.6 Grifols Competitive Strengths & Weaknesses
    7.4 Octapharma
        7.4.1 Octapharma Details
        7.4.2 Octapharma Major Business
        7.4.3 Octapharma Plasma-derived Therapies Product and Services
        7.4.4 Octapharma Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Octapharma Recent Developments/Updates
        7.4.6 Octapharma Competitive Strengths & Weaknesses
    7.5 Kedrion
        7.5.1 Kedrion Details
        7.5.2 Kedrion Major Business
        7.5.3 Kedrion Plasma-derived Therapies Product and Services
        7.5.4 Kedrion Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Kedrion Recent Developments/Updates
        7.5.6 Kedrion Competitive Strengths & Weaknesses
    7.6 LFB Group
        7.6.1 LFB Group Details
        7.6.2 LFB Group Major Business
        7.6.3 LFB Group Plasma-derived Therapies Product and Services
        7.6.4 LFB Group Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 LFB Group Recent Developments/Updates
        7.6.6 LFB Group Competitive Strengths & Weaknesses
    7.7 Biotest
        7.7.1 Biotest Details
        7.7.2 Biotest Major Business
        7.7.3 Biotest Plasma-derived Therapies Product and Services
        7.7.4 Biotest Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Biotest Recent Developments/Updates
        7.7.6 Biotest Competitive Strengths & Weaknesses
    7.8 BPL
        7.8.1 BPL Details
        7.8.2 BPL Major Business
        7.8.3 BPL Plasma-derived Therapies Product and Services
        7.8.4 BPL Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 BPL Recent Developments/Updates
        7.8.6 BPL Competitive Strengths & Weaknesses
    7.9 RAAS
        7.9.1 RAAS Details
        7.9.2 RAAS Major Business
        7.9.3 RAAS Plasma-derived Therapies Product and Services
        7.9.4 RAAS Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 RAAS Recent Developments/Updates
        7.9.6 RAAS Competitive Strengths & Weaknesses
    7.10 CBPO
        7.10.1 CBPO Details
        7.10.2 CBPO Major Business
        7.10.3 CBPO Plasma-derived Therapies Product and Services
        7.10.4 CBPO Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 CBPO Recent Developments/Updates
        7.10.6 CBPO Competitive Strengths & Weaknesses
    7.11 Hualan Bio
        7.11.1 Hualan Bio Details
        7.11.2 Hualan Bio Major Business
        7.11.3 Hualan Bio Plasma-derived Therapies Product and Services
        7.11.4 Hualan Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Hualan Bio Recent Developments/Updates
        7.11.6 Hualan Bio Competitive Strengths & Weaknesses
    7.12 Tiantan Bio
        7.12.1 Tiantan Bio Details
        7.12.2 Tiantan Bio Major Business
        7.12.3 Tiantan Bio Plasma-derived Therapies Product and Services
        7.12.4 Tiantan Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Tiantan Bio Recent Developments/Updates
        7.12.6 Tiantan Bio Competitive Strengths & Weaknesses
    7.13 Shuanglin Bio
        7.13.1 Shuanglin Bio Details
        7.13.2 Shuanglin Bio Major Business
        7.13.3 Shuanglin Bio Plasma-derived Therapies Product and Services
        7.13.4 Shuanglin Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 Shuanglin Bio Recent Developments/Updates
        7.13.6 Shuanglin Bio Competitive Strengths & Weaknesses
    7.14 Boya Bio
        7.14.1 Boya Bio Details
        7.14.2 Boya Bio Major Business
        7.14.3 Boya Bio Plasma-derived Therapies Product and Services
        7.14.4 Boya Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 Boya Bio Recent Developments/Updates
        7.14.6 Boya Bio Competitive Strengths & Weaknesses
    7.15 Yuanda Shuyang
        7.15.1 Yuanda Shuyang Details
        7.15.2 Yuanda Shuyang Major Business
        7.15.3 Yuanda Shuyang Plasma-derived Therapies Product and Services
        7.15.4 Yuanda Shuyang Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.15.5 Yuanda Shuyang Recent Developments/Updates
        7.15.6 Yuanda Shuyang Competitive Strengths & Weaknesses
    7.16 Weiguang Bio
        7.16.1 Weiguang Bio Details
        7.16.2 Weiguang Bio Major Business
        7.16.3 Weiguang Bio Plasma-derived Therapies Product and Services
        7.16.4 Weiguang Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.16.5 Weiguang Bio Recent Developments/Updates
        7.16.6 Weiguang Bio Competitive Strengths & Weaknesses
    7.17 Nanyue Bio
        7.17.1 Nanyue Bio Details
        7.17.2 Nanyue Bio Major Business
        7.17.3 Nanyue Bio Plasma-derived Therapies Product and Services
        7.17.4 Nanyue Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.17.5 Nanyue Bio Recent Developments/Updates
        7.17.6 Nanyue Bio Competitive Strengths & Weaknesses
    7.18 KM Biologics
        7.18.1 KM Biologics Details
        7.18.2 KM Biologics Major Business
        7.18.3 KM Biologics Plasma-derived Therapies Product and Services
        7.18.4 KM Biologics Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024)
        7.18.5 KM Biologics Recent Developments/Updates
        7.18.6 KM Biologics Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Plasma-derived Therapies Industry Chain
    8.2 Plasma-derived Therapies Upstream Analysis
    8.3 Plasma-derived Therapies Midstream Analysis
    8.4 Plasma-derived Therapies Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Plasma-derived Therapies Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Table 2. World Plasma-derived Therapies Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
 Table 3. World Plasma-derived Therapies Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
 Table 4. World Plasma-derived Therapies Revenue Market Share by Region (2019-2024), (by Headquarter Location)
 Table 5. World Plasma-derived Therapies Revenue Market Share by Region (2025-2030), (by Headquarter Location)
 Table 6. Major Market Trends
 Table 7. World Plasma-derived Therapies Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
 Table 8. World Plasma-derived Therapies Consumption Value by Region (2019-2024) & (USD Million)
 Table 9. World Plasma-derived Therapies Consumption Value Forecast by Region (2025-2030) & (USD Million)
 Table 10. World Plasma-derived Therapies Revenue by Player (2019-2024) & (USD Million)
 Table 11. Revenue Market Share of Key Plasma-derived Therapies Players in 2023
 Table 12. World Plasma-derived Therapies Industry Rank of Major Player, Based on Revenue in 2023
 Table 13. Global Plasma-derived Therapies Company Evaluation Quadrant
 Table 14. Head Office of Key Plasma-derived Therapies Players
 Table 15. Plasma-derived Therapies Market: Company Product Type Footprint
 Table 16. Plasma-derived Therapies Market: Company Product Application Footprint
 Table 17. Plasma-derived Therapies Mergers & Acquisitions Activity
 Table 18. United States VS China Plasma-derived Therapies Revenue Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 19. United States VS China Plasma-derived Therapies Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 20. United States Based Plasma-derived Therapies Companies, Headquarters (States, Country)
 Table 21. United States Based Companies Plasma-derived Therapies Revenue, (2019-2024) & (USD Million)
 Table 22. United States Based Companies Plasma-derived Therapies Revenue Market Share (2019-2024)
 Table 23. China Based Plasma-derived Therapies Companies, Headquarters (Province, Country)
 Table 24. China Based Companies Plasma-derived Therapies Revenue, (2019-2024) & (USD Million)
 Table 25. China Based Companies Plasma-derived Therapies Revenue Market Share (2019-2024)
 Table 26. Rest of World Based Plasma-derived Therapies Companies, Headquarters (Province, Country)
 Table 27. Rest of World Based Companies Plasma-derived Therapies Revenue (2019-2024) & (USD Million)
 Table 28. Rest of World Based Companies Plasma-derived Therapies Revenue Market Share (2019-2024)
 Table 29. World Plasma-derived Therapies Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Table 30. World Plasma-derived Therapies Market Size Value by Type (2019-2024) & (USD Million)
 Table 31. World Plasma-derived Therapies Market Size by Type (2025-2030) & (USD Million)
 Table 32. World Plasma-derived Therapies Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Table 33. World Plasma-derived Therapies Market Size by Application (2019-2024) & (USD Million)
 Table 34. World Plasma-derived Therapies Market Size by Application (2025-2030) & (USD Million)
 Table 35. Takeda Basic Information, Manufacturing Base and Competitors
 Table 36. Takeda Major Business
 Table 37. Takeda Plasma-derived Therapies Product and Services
 Table 38. Takeda Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 39. Takeda Recent Developments/Updates
 Table 40. Takeda Competitive Strengths & Weaknesses
 Table 41. CSL Basic Information, Manufacturing Base and Competitors
 Table 42. CSL Major Business
 Table 43. CSL Plasma-derived Therapies Product and Services
 Table 44. CSL Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 45. CSL Recent Developments/Updates
 Table 46. CSL Competitive Strengths & Weaknesses
 Table 47. Grifols Basic Information, Manufacturing Base and Competitors
 Table 48. Grifols Major Business
 Table 49. Grifols Plasma-derived Therapies Product and Services
 Table 50. Grifols Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 51. Grifols Recent Developments/Updates
 Table 52. Grifols Competitive Strengths & Weaknesses
 Table 53. Octapharma Basic Information, Manufacturing Base and Competitors
 Table 54. Octapharma Major Business
 Table 55. Octapharma Plasma-derived Therapies Product and Services
 Table 56. Octapharma Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 57. Octapharma Recent Developments/Updates
 Table 58. Octapharma Competitive Strengths & Weaknesses
 Table 59. Kedrion Basic Information, Manufacturing Base and Competitors
 Table 60. Kedrion Major Business
 Table 61. Kedrion Plasma-derived Therapies Product and Services
 Table 62. Kedrion Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 63. Kedrion Recent Developments/Updates
 Table 64. Kedrion Competitive Strengths & Weaknesses
 Table 65. LFB Group Basic Information, Manufacturing Base and Competitors
 Table 66. LFB Group Major Business
 Table 67. LFB Group Plasma-derived Therapies Product and Services
 Table 68. LFB Group Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 69. LFB Group Recent Developments/Updates
 Table 70. LFB Group Competitive Strengths & Weaknesses
 Table 71. Biotest Basic Information, Manufacturing Base and Competitors
 Table 72. Biotest Major Business
 Table 73. Biotest Plasma-derived Therapies Product and Services
 Table 74. Biotest Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 75. Biotest Recent Developments/Updates
 Table 76. Biotest Competitive Strengths & Weaknesses
 Table 77. BPL Basic Information, Manufacturing Base and Competitors
 Table 78. BPL Major Business
 Table 79. BPL Plasma-derived Therapies Product and Services
 Table 80. BPL Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 81. BPL Recent Developments/Updates
 Table 82. BPL Competitive Strengths & Weaknesses
 Table 83. RAAS Basic Information, Manufacturing Base and Competitors
 Table 84. RAAS Major Business
 Table 85. RAAS Plasma-derived Therapies Product and Services
 Table 86. RAAS Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 87. RAAS Recent Developments/Updates
 Table 88. RAAS Competitive Strengths & Weaknesses
 Table 89. CBPO Basic Information, Manufacturing Base and Competitors
 Table 90. CBPO Major Business
 Table 91. CBPO Plasma-derived Therapies Product and Services
 Table 92. CBPO Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 93. CBPO Recent Developments/Updates
 Table 94. CBPO Competitive Strengths & Weaknesses
 Table 95. Hualan Bio Basic Information, Manufacturing Base and Competitors
 Table 96. Hualan Bio Major Business
 Table 97. Hualan Bio Plasma-derived Therapies Product and Services
 Table 98. Hualan Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 99. Hualan Bio Recent Developments/Updates
 Table 100. Hualan Bio Competitive Strengths & Weaknesses
 Table 101. Tiantan Bio Basic Information, Manufacturing Base and Competitors
 Table 102. Tiantan Bio Major Business
 Table 103. Tiantan Bio Plasma-derived Therapies Product and Services
 Table 104. Tiantan Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 105. Tiantan Bio Recent Developments/Updates
 Table 106. Tiantan Bio Competitive Strengths & Weaknesses
 Table 107. Shuanglin Bio Basic Information, Manufacturing Base and Competitors
 Table 108. Shuanglin Bio Major Business
 Table 109. Shuanglin Bio Plasma-derived Therapies Product and Services
 Table 110. Shuanglin Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 111. Shuanglin Bio Recent Developments/Updates
 Table 112. Shuanglin Bio Competitive Strengths & Weaknesses
 Table 113. Boya Bio Basic Information, Manufacturing Base and Competitors
 Table 114. Boya Bio Major Business
 Table 115. Boya Bio Plasma-derived Therapies Product and Services
 Table 116. Boya Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 117. Boya Bio Recent Developments/Updates
 Table 118. Boya Bio Competitive Strengths & Weaknesses
 Table 119. Yuanda Shuyang Basic Information, Manufacturing Base and Competitors
 Table 120. Yuanda Shuyang Major Business
 Table 121. Yuanda Shuyang Plasma-derived Therapies Product and Services
 Table 122. Yuanda Shuyang Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 123. Yuanda Shuyang Recent Developments/Updates
 Table 124. Yuanda Shuyang Competitive Strengths & Weaknesses
 Table 125. Weiguang Bio Basic Information, Manufacturing Base and Competitors
 Table 126. Weiguang Bio Major Business
 Table 127. Weiguang Bio Plasma-derived Therapies Product and Services
 Table 128. Weiguang Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 129. Weiguang Bio Recent Developments/Updates
 Table 130. Weiguang Bio Competitive Strengths & Weaknesses
 Table 131. Nanyue Bio Basic Information, Manufacturing Base and Competitors
 Table 132. Nanyue Bio Major Business
 Table 133. Nanyue Bio Plasma-derived Therapies Product and Services
 Table 134. Nanyue Bio Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 135. Nanyue Bio Recent Developments/Updates
 Table 136. Nanyue Bio Competitive Strengths & Weaknesses
 Table 137. KM Biologics Basic Information, Manufacturing Base and Competitors
 Table 138. KM Biologics Major Business
 Table 139. KM Biologics Plasma-derived Therapies Product and Services
 Table 140. KM Biologics Plasma-derived Therapies Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
 Table 141. KM Biologics Recent Developments/Updates
 Table 142. KM Biologics Competitive Strengths & Weaknesses
 Table 143. Global Key Players of Plasma-derived Therapies Upstream (Raw Materials)
 Table 144. Global Plasma-derived Therapies Typical Customers


List of Figures
 Figure 1. Plasma-derived Therapies Picture
 Figure 2. World Plasma-derived Therapies Total Revenue: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Plasma-derived Therapies Total Revenue (2019-2030) & (USD Million)
 Figure 4. World Plasma-derived Therapies Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
 Figure 5. World Plasma-derived Therapies Revenue Market Share by Region (2019-2030), (by Headquarter Location)
 Figure 6. United States Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 7. China Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 8. Europe Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 9. Japan Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 10. South Korea Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 11. ASEAN Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 12. India Based Company Plasma-derived Therapies Revenue (2019-2030) & (USD Million)
 Figure 13. Plasma-derived Therapies Market Drivers
 Figure 14. Factors Affecting Demand
 Figure 15. World Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 16. World Plasma-derived Therapies Consumption Value Market Share by Region (2019-2030)
 Figure 17. United States Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 18. China Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 19. Europe Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 20. Japan Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 21. South Korea Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 22. ASEAN Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 23. India Plasma-derived Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 24. Producer Shipments of Plasma-derived Therapies by Player Revenue ($MM) and Market Share (%): 2023
 Figure 25. Global Four-firm Concentration Ratios (CR4) for Plasma-derived Therapies Markets in 2023
 Figure 26. Global Four-firm Concentration Ratios (CR8) for Plasma-derived Therapies Markets in 2023
 Figure 27. United States VS China: Plasma-derived Therapies Revenue Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Plasma-derived Therapies Consumption Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. World Plasma-derived Therapies Market Size by Type, (USD Million), 2019 & 2023 & 2030
 Figure 30. World Plasma-derived Therapies Market Size Market Share by Type in 2023
 Figure 31. Immune Globulin
 Figure 32. Coagulation Factor
 Figure 33. Albumin
 Figure 34. Other
 Figure 35. World Plasma-derived Therapies Market Size Market Share by Type (2019-2030)
 Figure 36. World Plasma-derived Therapies Market Size by Application, (USD Million), 2019 & 2023 & 2030
 Figure 37. World Plasma-derived Therapies Market Size Market Share by Application in 2023
 Figure 38. Hospital
 Figure 39. Retail Pharmacy
 Figure 40. Other
 Figure 41. World Plasma-derived Therapies Market Size Market Share by Application (2019-2030)
 Figure 42. Plasma-derived Therapies Industrial Chain
 Figure 43. Methodology
 Figure 44. Research Process and Data Source

Companies Mentioned

Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics